Abstract: OBJECTIVE To study the clinical efficacy and safety of Tanreqing in treatment of heart failure patients with pulmonary infection, so as to provide the basis for improving clinical efficacy. METHODS A total of 80 cases of patients with heart failure and pulmonary infection treated in hospital from Oct. 2013 to Oct. 2015 were selected, and randomly divided into two groups according to the random number method, with 40 cases in each group. Patients in control group were treated with conventional therapy, and in experimental group were treated with Tanreqing based on control group. The clinical efficacy of the two group were compared, and the data were analyzed by SPSS 18.0. RESULTS The total effective rate of experimental group was 95.0%, significantly higher than 85.0% of control group (P<0.05), and the therapy adverse reactions rate of experimental group was 7.5%, significantly lower than 17.5% of control group (P<0.05). CONCLUSION Conventional treatment combined with Tanreqing has better efficacy in treatment of heart failure patients with pulmonary infection, which can improve the clinical efficacy, and is safety, so it should be widely applied.